GlassScriptPhysician profile
Zachary Bloomgarden
NPI 1700892635
$35,042.09
in general payments reported to CMS, 2019-2025
31 companies · $7,519 in 2025
The $7,519 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $3,701 · 2021: $508 · 2022: $7,342 · 2023: $717 · 2024: $1,546 · 2025: $7,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,460 · Food and Beverage: $3,647 · Travel and Lodging: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,460.00 |
| Food and Beverage | $3,647.25 |
| Travel and Lodging | $1,674.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $9,234.72 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $7,523.15 | 2019-2025 | Jardiance |
| Mannkind Corporation | $6,865.28 | 2022 | |
| Astrazeneca Uk Limited | $3,244.85 | 2019 | |
| Boehringer Ingelheim (China) Investment Co., LTD. | $2,240.00 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,440.00 | 2020 | |
| Radiometer America, INC | $672.00 | 2019 | |
| Abbott Laboratories | $465.13 | 2022-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $464.73 | 2023-2025 | |
| Esperion Therapeutics, INC. | $413.69 | 2021-2025 | Nexletol |
| Lilly USA, LLC | $376.22 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $316.96 | 2019-2024 | Repatha |
| Novo Nordisk INC | $284.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Zealand Pharma US, INC. | $188.52 | 2021 | |
| Merck Sharp & Dohme LLC | $171.13 | 2023-2025 | Verquvo, Steglujan, Steglatro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $141.93 | 2019-2025 | Wainua, Farxiga |
| Tandem Diabetes Care, INC. | $131.80 | 2022 | |
| Madrigal Pharmaceuticals | $128.12 | 2025 | Rezdiffra |
| Glaxosmithkline, LLC. | $127.37 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Corcept Therapeutics | $99.96 | 2021-2024 | Korlym |
| Novartis Pharmaceuticals Corporation | $96.47 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $81.27 | 2019 | |
| Abbvie INC. | $71.41 | 2023-2024 | Ubrelvy, Synthroid |
| Exact Sciences Corporation | $57.43 | 2023-2025 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $42.47 | 2024 | Edarbi |
| Pfizer INC. | $32.16 | 2024 | |
| Janssen Pharmaceuticals, INC | $30.07 | 2024 | Xarelto |
| Insulet Corporation | $27.91 | 2024 | Omnipod |
| Boston Scientific Corporation | $25.90 | 2024 | Watchman Flx |
| Kiniksa Pharmaceuticals International, Plc | $25.60 | 2024 | Arcalyst |
| Sumitomo Pharma America, INC. | $20.95 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Bloomgarden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.